Agnieszka Poniewiera-Palucha
Smętna Street 12
Krakow, MA 31343, Poland
Krakow, MA 31343, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Modulation of Metabotropic Glutamate Receptors as a Strategy to Improve the Efficacy and Safety of Ketamine as an Antidepressant.
Journal: Cells
Published: November 17, 2025
Coadministration of scopolamine and mGlu2 NAM VU6001966 as a novel antidepressant approach: Lowering effective dose and reducing cognitive side effects.
Journal: Psychopharmacology
Published: July 21, 2025
(R)-ketamine induces mGlu5 receptor-dependent antidepressant-like effects in the chronic unpredictable mild stress model of depression in mice.
Journal: Psychopharmacology
Published: March 07, 2025
Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior.
Journal: Pharmacology, biochemistry, and behavior
Published: February 11, 2025
Depression-like effects induced by chronic unpredictable mild stress in mice are rapidly reversed by a partial negative allosteric modulator of mGlu5 receptor, M-5MPEP.
Journal: Psychopharmacology
Published: September 25, 2024
Maternal fluoxetine impairs synaptic transmission and plasticity in the medial prefrontal cortex and alters the structure and function of dorsal raphe nucleus neurons in offspring mice.
Journal: Pharmacology, biochemistry, and behavior
Published: June 19, 2024
Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation.
Journal: Pharmacological reports : PR
Published: April 12, 2024
Partial mGlu5 receptor NAM, M-5MPEP, induces rapid and sustained antidepressant-like effects in the BDNF-dependent mechanism and enhances (R)-ketamine action in mice.
Journal: Pharmacological reports : PR
Published: January 23, 2024
The Antidepressant-like Activity and Cognitive Enhancing Effects of the Combined Administration of (R)-Ketamine and LY341495 in the CUMS Model of Depression in Mice Are Related to the Modulation of Excitatory Synaptic Transmission and LTP in the PFC.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 05, 2022
The role of mGlu2/3 receptor antagonists in the enhancement of the antidepressant-like effect of ketamine.
Journal: Pharmacology, biochemistry, and behavior
Published: May 10, 2022
Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 14, 2021
The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice.
Journal: Behavioural brain research
Published: June 21, 2021
Last Updated: 09/26/2026